DE60140966D1 - Verfahren zur Verbesserung von Krebstherapie - Google Patents

Verfahren zur Verbesserung von Krebstherapie

Info

Publication number
DE60140966D1
DE60140966D1 DE60140966T DE60140966T DE60140966D1 DE 60140966 D1 DE60140966 D1 DE 60140966D1 DE 60140966 T DE60140966 T DE 60140966T DE 60140966 T DE60140966 T DE 60140966T DE 60140966 D1 DE60140966 D1 DE 60140966D1
Authority
DE
Germany
Prior art keywords
cancer therapy
treatment
improving cancer
methods
retinoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60140966T
Other languages
English (en)
Inventor
David Tice
Diane Pennica
Paul Polakis
Wayne Szeto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/759,056 external-priority patent/US7173115B2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE60140966D1 publication Critical patent/DE60140966D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
DE60140966T 2000-08-29 2001-07-10 Verfahren zur Verbesserung von Krebstherapie Expired - Lifetime DE60140966D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22891400P 2000-08-29 2000-08-29
US09/759,056 US7173115B2 (en) 2000-01-13 2001-01-11 Stra6 polypeptides
US09/901,812 US20020173461A1 (en) 2000-01-13 2001-07-10 Methods for enhancing the efficacy of cancer therapy

Publications (1)

Publication Number Publication Date
DE60140966D1 true DE60140966D1 (de) 2010-02-11

Family

ID=27397886

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60140966T Expired - Lifetime DE60140966D1 (de) 2000-08-29 2001-07-10 Verfahren zur Verbesserung von Krebstherapie

Country Status (10)

Country Link
EP (2) EP1666600B1 (de)
JP (1) JP2004507251A (de)
KR (1) KR20080068147A (de)
AT (1) ATE453718T1 (de)
AU (1) AU2001271938A1 (de)
CA (1) CA2420867C (de)
DE (1) DE60140966D1 (de)
ES (1) ES2337696T3 (de)
NZ (1) NZ524230A (de)
WO (1) WO2002018608A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030021788A1 (en) * 2000-03-23 2003-01-30 Diane Pennica Novel human STRA6-like protein and nucleic acids encoding the same
AU2003223477A1 (en) * 2002-04-05 2003-10-27 University Of Utah Research Foundation Regulation of a novel colon specific retinol dehydrogenase by apc and cdx2
CA2483449A1 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
CA2592390A1 (en) 2004-12-22 2006-06-29 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
TWI407971B (zh) * 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
EP2710035B1 (de) 2011-05-16 2017-04-12 F. Hoffmann-La Roche AG Fgfr1-agonisten und anwendungsverfahren
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
CN114574378B (zh) * 2022-04-11 2023-09-22 浙江大学 一种生产视黄酸的基因工程菌及其构建方法和应用
CN117625626B (zh) * 2024-01-25 2024-04-16 中国农业科学院植物保护研究所 RNAi在提高苏云金芽胞杆菌杀虫蛋白防治二化螟或草地贪夜蛾效果中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997852A (en) * 1987-08-26 1991-03-05 Ohio State University Research Foundation Method and composition for achieving cancer chemopreventive and chemotherapeutic activity
US5731167A (en) * 1992-01-17 1998-03-24 The United States Of America As Represented By The Department Of Health And Human Services Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy
AU2582897A (en) 1996-03-15 1997-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
DK1246917T3 (da) * 2000-01-13 2009-06-08 Genentech Inc Humane Stra6-polypeptider

Also Published As

Publication number Publication date
CA2420867A1 (en) 2002-03-07
WO2002018608A3 (en) 2003-06-26
ES2337696T3 (es) 2010-04-28
KR20080068147A (ko) 2008-07-22
EP1666600B1 (de) 2009-12-30
WO2002018608A9 (en) 2003-08-07
JP2004507251A (ja) 2004-03-11
NZ524230A (en) 2006-05-26
WO2002018608A2 (en) 2002-03-07
AU2001271938A1 (en) 2002-03-13
EP1341923A2 (de) 2003-09-10
ATE453718T1 (de) 2010-01-15
CA2420867C (en) 2013-02-05
EP1666600A1 (de) 2006-06-07

Similar Documents

Publication Publication Date Title
ATE411399T1 (de) Behandlung der huntington's krankheit mit epa
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
ATE519862T1 (de) Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von gebärmutterhalskrebs
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
CR9512A (es) Metodos para el tratamiento de tumores de cerebro con anticuerpos
ATE299860T1 (de) Vebindungen zur modulation des rage-rezeptors
DE60020529D1 (de) Antikörper zur krebsbehandlung und -diagnose
CY1108960T1 (el) Αντισωματα αποκλεισμου cripto και οι χρησεις τους
WO2004050707A3 (de) Tumorspezifische erkennungsmoleküle
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
DE60029092D1 (de) Verfahren zur detektion von nukleinsäuren, welche auf krebs hinweisen
DE60140966D1 (de) Verfahren zur Verbesserung von Krebstherapie
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
ATE531813T1 (de) System zur überwachung einer bakteriellen tumorbehandlung
NO20054631L (no) Antistoff mot tumorspesifikt antigen som mal
HK1049185A1 (zh) 可改螢光蛋白
DE60124526D1 (de) Methode zur identifizierung von helicobacter antigenen
ATE444488T1 (de) Non-apoptotische formen des zelltods und verfahren zur modulation
ES2502366T3 (es) Inducción de inmunidad tumoral por variantes de proteína de unión a folato
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
DE60111620D1 (de) Aktiviertes protein c zur behandlung von pankreatitis
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition